Clinical Trials Logo

Ampullary Carcinoma clinical trials

View clinical trials related to Ampullary Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06062485 Not yet recruiting - Ampullary Carcinoma Clinical Trials

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Start date: October 2023
Phase: Phase 2
Study type: Interventional

A Phase Ⅱ, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With recurrent or metastatic ampulla tumors.

NCT ID: NCT02238613 Recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer

Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether radioactive stents and common used plastic stents are effective and safety in the treatment of unresectable biliary tract cancer.

NCT ID: NCT01844245 Completed - Cholangiocarcinoma Clinical Trials

Endobiliary RFA for Unresectable Malignant Biliary Strictures

Start date: May 2013
Phase: N/A
Study type: Interventional

Only a small proportion of patients with cholangiocarcinoma or ampullary carcinoma are suitable for surgical resection. The endoscopic or percutaneous transhepatic biliary drainage is accepted approaches for the relief of jaundice in malignant biliary obstruction. But restoration of bile flow have few improvement of the survival of cancer patient. By using endobiliary radiofrequency energy to destruct the tumorous tissue may delay tumour growth, which might improve the survival of patients. The feasibility and safety of this technique using HabibTM EndoHBP probe has been evident. The aims of this randomised, controlled, multicentre study is to evaluate whether endobiliary radiofrequency ablation(RFA) can improve the median survival of patients with unresectable biliary malignancy.

NCT ID: NCT00753675 Completed - Clinical trials for Biliary Tract Cancer

Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

VANGOGH
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic) biliary tract cancer.